吲哚菁绿荧光导航和三维可视化腹腔镜精准手术治疗原发性肝癌患者应用研究*

doi:10.3969/j.issn.1672-5069.2021.04.027

Abstract

Abstract: Objective The aim of this study was to investigate the application of indocyanine green fluorescence navigation technology and three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer (PLC). Methods A total of 114 patients with PLC were admitted to our hospital between January 2015 and December 2019, and were randomly divided into observation (n=57) and control group (n=57). The patients in the control received indocyanine green fluorescence navigation and laparoscopic hepatectomy and those in the combination received indocyanine green fluorescence navigation and laparoscopic hepatectomy under three-dimensional visualization. Serum cortisol (COR) and interleukin 6 (IL-6) were detected. Results The hospital stay were(6.9±2.3)d and (7.5±2.5)d (P>0.05) in the combination and control group, the satisfaction rates of fluorescent staining in the two groups were 91.2% and 91.2%(P>0.05), while the operation time and blood loss in the combination were (181.0±59.6)min and (96.9±21.7)ml, both significantly shorter or less than [(210.4±86.5)min and (106.3±25.0)ml, respectively,P<0.05] in the control; there was no significant differences as respect to the liver function tests between the two groups (P<0.05); after operation, serum COR and IL-6 levels in the combination were (264.3±33.8)mmol/L and (108.0±13.8)pg/ml, both significantly lower than [(288.0±34.5)mmol/L and (116.1±15.8)pg/ml, respectively, P<0.05] in the control; after operation, the incidences of bile leakage, pleural effusion and ascites, and fever in the two groups were 24.6% vs. 36.8%, without significant differences (P>0.05). Conclusion The application of indocyanine green fluorescence navigation technology and laparoscopic hepatectomy under three-dimensional visualization might help remove the tumors precisely and shorten operational times, which warrants more clinical observations.

Key words: Hepatoma, Three-dimensional visualization, Indocyanine green fluorescence navigation technology, Laparoscopic hepatectomy, Therapy

Liu Yongchang, Zhao Diantang, Sun Qifeng, et al. Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer[J]. Journal of Practical Hepatology, 2021, 24(4): 561-564.

References

[1] Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma:from diagnosis to treatment. Surg Oncol, 2016, 25(2):74-85.
[2] Massarweh NN, El-Serag HB. Epidemiology ofhepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control, 2017, 24(3):107-117.
[3] Luo F, Zhou J, Yan W. A comparative study of laparoscopic precise hepatectomy with conventional open hepatectomy in the treatment of primary hepatocellular cancer. J Buon, 2019, 24(5):1943-1949.
[4] Boogerd LS, Handgraaf HJ, Lam HD,et al. Laparoscopic detection and resection of occult liver tumors of multiple cancer types using real-time near-infrared fluorescence guidance. Surg Endosc, 2017, 31(2):952-961.
[5] Kokudo N, Takemura N, Ito K,et al. The history of liver surgery: achievements over the past 50 years. Ann Gastroenterol Surg, 2020, 4(2):109-117.
[6] Fang C, An J, Bruno A,et al. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. Hepatol Int, 2020, 14(4):437-453.
[7] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版). 中华肝脏病杂志, 2017, 25(12):886-895.
[8] Kaibori M, Kon M, Kitawaki T,et al. Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2017, 24(11):616-626.
[9] Kaibori M, Matsui K, Ishizaki M,et al. Evaluation of fluorescence imaging with indocyanine green in hepatocellular carcinoma. Cancer Imaging, 2016, 6(16):6.
[10] 王鹏飞, 陈明易, 卢实春, 等. 吲哚菁绿荧光引导腹腔镜解剖性肝脏Ⅶ段切除手术流程. 中华肝胆外科杂志, 2019, 25(2):137-139.
[11] 马家豪, 王连才, 王亚峰,等. 吲哚菁绿荧光融合影像技术在腹腔镜肝癌解剖性肝切除术中的应用. 中华普通外科杂志, 2019, 34(7)::586-589.
[12] 王晓颖, 高强, 朱晓东, 等. 腹腔镜超声联合三维可视化技术引导门静脉穿刺吲哚菁绿荧光染色在精准解剖性肝段切除术中的应用. 中华消化外科杂志, 2018, 17(5):452-458.
[13] Zhang B, Chen Z, Hu X,et al. Application of three-dimensional visualization technology in laparoscopic surgery for pheochromocytoma/paraganglioma: a single-center experience. J Laparoendosc Adv Surg Tech A, 2018, 28(8):997-1002.
[14] Fukutomi S, Nomura Y, Nakashima O,et al. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford), 2017, 19(12):1119-1125.
[15] Jang JY, Han HS, Yoon YS,et al. Three-dimensional laparoscopic anatomical segment 8 liver resection with glissonian approach. Ann Surg Oncol, 2017, 24(6):1606-1609.
[16] Mizuno T, Sheth R, Yamamoto M,et al. Laparoscopic glissonean pedicle transection (Takasaki) for negative fluorescent counterstaining of segment 6. Ann Surg Oncol, 2017, 24(4):1046-1047.
[17] Timaran Montenegro DE, Torres Ramirez CA, Mateo CYS,et al. CT-based hepatic residual volume and predictors of outcomes of patients with hepatocellular carcinoma unsuitable for surgical therapy undergoing transarterial chemoembolization. Acad Radiol, 2020, 27(6):807-814.
[18] Mizutani Y, Hirai T, Nagamachi S,et al. Prediction of posthepatectomy liver failure proposed by the international study group of liver surgery: residual liver function estimation with 99mTc-galactosyl human serum albumin scintigraphy. Clin Nucl Med, 2018,43(2):77-81.
[19] Guan TP, Fang CH, Yang J,et al. A comparison between three-dimensional visualization guided hepatectomy and ultrasonography guided radiofrequency ablation in the treatment of small hepatocellular carcinoma within the Milan criteria. Biomed Res Int, 2016, 20(16):893-901.
[20] 吴晓龙, 毕新宇, 李智宇, 等.术后中性粒细胞和淋巴细胞比值与肝细胞癌切除术后复发及患者生存的关系. 中华肿瘤杂志, 2018, 40(5):365-371.

Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.
[2]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[3]	Chen Wei, Wei Tao, Yang Lan, et al. Expression of NLRP3 inflammasome in cancerous tissues of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 544-547.
[4]	Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.
[5]	Wang Xuemei, Zhang Yao, Yang Xueping, et al. Clinical application of ultrasound-guided percutaneous aspiration and percutaneous catheter drainage for treatment of liver abscess patients with or without AIDS [J]. Journal of Practical Hepatology, 2021, 24(4): 573-576.
[6]	Tang Wentao, Huang Hui, Cai Chanjuan. Long-term curative effects of transarterial embolization with pingyangmycin-lipiodol suspension in the treatment of patients with hepatic hemangioma [J]. Journal of Practical Hepatology, 2021, 24(4): 581-584.
[7]	Fu Qianguang, Li Qian, Feng Xiaoxue, et al. Clinical efficacy of laparoscopic common bile duct exploration and laparoscopic cholecystectomy combination in the treatment of patients with cholecystolithiasis and choledocholithiasis [J]. Journal of Practical Hepatology, 2021, 24(4): 589-592.
[8]	Wang Qunxian, Wang Yunchuan, Chen Youying. Effect of sevoflurane inhalation at different times during anesthesia in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(4): 597-599.
[9]	An Xiquan, Li Yan, Menggen Caicike. Clinical observation of tenofovir and sorafenib in the treatment of patients with hepatitis B associated advanced primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 600-602.
[10]	Bi Zaihong, Hanbai Yila, Wang Bingyuan. Simvastatin: a newface for treatment of patients with chronic liver disease [J]. Journal of Practical Hepatology, 2021, 24(4): 603-606.
[11]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[12]	Luo Weixin, Liu Chaoqun, Xu Leibo, et al. Effects of exosomes derived from rat liver cancer cells with different lung metastasis potentials on the transcriptome of macrophages [J]. Journal of Practical Hepatology, 2021, 24(3): 312-318.
[13]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[14]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[15]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.